1404537-13-8

Basic information

• Product Name: C₃₁H₃₃N₇O₃*ClH
• CAS NO: 1404537-13-8
• Molecular Weight: 588.109
• Mol File: 1404537-13-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₃₁H₃₃N₇O₃*ClH(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₁H₃₃N₇O₃*ClH(1404537-13-8)
• EPA Substance Registry System: C₃₁H₃₃N₇O₃*ClH(1404537-13-8)

Safety Data

• Hazardous Substances Data: 1404537-13-8(Hazardous Substances Data)

Upstream product

• 1404530-78-4 1-[1-(4-aminophenyl)-5-methyl-1H-pyrazol-4-yl]butan-1-one 
• 1404530-84-2 1-[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]butan-1-one 
• 1404530-82-0 ethyl 2-{[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]carbonyl}butanoate 
• 1404530-79-5 ethyl 3-[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]-3-oxopropanoate 
• 350-46-9 4-Fluoronitrobenzene 
• 260973-82-8 5-methyl-1-(4-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 1404532-12-2 5-bromo-1-(2-methoxy-2-oxoethyl)-1H-indole-3-carboxylic acid 
• 10406-06-1 5-bromo-1H-indole-3-carboxylic acid 
• 32387-18-1 1-(5-bromo-1H-indol-3-yl)-2,2,2-trifluoroethanone 
• 1404530-54-6 1-(5-methyl-1H-pyrazol-4-yl)butan-1-one 
• 10075-50-0 5-bromo-1H-indole 
• 109-01-3 1-methyl-piperazine 
• 1404533-19-2 sodium {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5-cyano-indol-1-yl}acetate 

Relevant articles and documents

N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist

In the search of a potential backup for clopidogrel, we have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low micromolar binding activity, we report here the main steps of the optimization process leading to the identification of the preclinical candidate SAR216471. It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. SAR216471 displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.